Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

On April 3, 2024 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that through its collaboration agreement with a large network of integrated, community-based oncology practices, the Company has added multiple clinical trial sites for its Acclaim-3 clinical study of Reqorsa Immunogene Therapy (quaratusugene ozeplasmid) in combination with Genentech’s Tecentriq (atezolizumab) to treat patients with extensive-stage small cell lung cancer (ES-SCLC) (Press release, Genprex, APR 3, 2024, View Source [SID1234641739]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With the majority of oncology patients treated by community-based oncology practices, this collaboration to expand our Acclaim-3 clinical study to additional trial sites is important as it may accelerate patient enrollment, provide access to our innovative clinical trial treatment for patients outside of major urban or academic settings, broaden the geographic reach of our study to more ES-SCLC patients in need and potentially benefit ES-SCLC patients who currently have limited benefit from existing treatment options," said Rodney Varner, President, Chairman and Chief Executive Officer at Genprex. "This collaboration leverages the broad network of oncologists and enables patients to access our promising treatment at the office of their primary oncologist, while allowing Genprex to more efficiently and expeditiously accelerate our Acclaim-3 clinical trial."

ES-SCLC is an aggressive form of lung cancer that is presently incurable. ES-SCLC has a median progression free survival (PFS) of 5.4 months from the start of initial therapy. However, once patients start receiving maintenance therapy with Tecentriq they have a median PFS of only 2.6 months. The combination of REQORSA and Tecentriq as maintenance therapy may provide a new therapeutic option for the treatment of small cell lung cancer (SCLC).

Genprex has a novel cancer treatment platform that re-expresses tumor suppressor genes in cancers. Tumor suppressor genes are often deleted or inactivated early in the process of cancer development. REQORSA, the Company’s lead drug candidate, contains a plasmid that expresses TUSC2, a tumor suppressor gene protein. Nearly 100% of SCLCs have reduced or no TUSC2 protein expression, and 41% of SCLCs completely lack TUSC2 protein expression. Preclinical studies in mice support the hypothesis that re-expressing the TUSC2 protein may lead to improved clinical efficacy in combination with Tecentriq.

"We look forward to continuing our relationship with this large, nationwide network of oncology practices for our Acclaim-3 clinical trial in SCLC, which is the same partner we used for our Acclaim-1 clinical trial in NSCLC," said Mark Berger, M.D., Chief Medical Officer at Genprex. "Based on the success we experienced in patient enrollment from our other lung cancer clinical trial, we believe this collaboration will enhance our patient enrollment for Acclaim-3 and help us to expeditiously begin treating patients in need."

About the Acclaim-3 Clinical Trial

The Acclaim-3 clinical trial is a Phase 1/2 open-label, dose escalation and clinical response study of maintenance therapy evaluating Reqorsa in combination with Tecentriq in patients with ES-SCLC. The Acclaim-3 clinical trial will enroll patients who did not develop tumor progression after receiving Tecentriq and chemotherapy as standard initial treatment, and who are therefore eligible for maintenance therapy.

The Phase 1 dose escalation portion of the Acclaim-3 clinical study was initially expected to enroll up to 12 patients at three to five U.S. clinical sites, which has now doubled to approximately 10 U.S. clinical sites, to determine the Maximum Tolerated Dose (MTD). If no dose limiting toxicities occur during the Phase 1 study, the highest dose evaluated will be the Recommended Phase 2 Dose. The Phase 2 portion of the study is expected to enroll approximately 50 patients at ten to fifteen U.S. sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. Genprex expects to initiate the Phase 2 expansion study in the second half of 2024.

The primary endpoint of the Phase 2 portion of the trial is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq treatment in patients with ES-SCLC. Patients will also be followed for survival. A Phase 2 futility analysis will be performed after the 25th patient enrolled and treated reaches 18 weeks of follow up.

Genprex has received U.S. Food and Drug Administration (FDA) Ophran Drug and Fast Track designations for the Acclaim-3 patient population. Additional information about the Acclaim-3 clinical trial can be found by visiting ClinicalTrials.gov.

Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

On April 3, 2024 Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, reported that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 2:15 PM ET (Press release, Fate Therapeutics, APR 3, 2024, View Source [SID1234641738]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast, if recorded, of each presentation can be accessed under "Events & Presentations" in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

On April 3, 2024 CytomX Therapeutics, Inc. reported the achievement of a second clinical candidate nomination under the companies’ TCB collaboration with Astellas, triggering a $5 million milestone payment to CytomX (Press release, CytomX Therapeutics, APR 3, 2024, View Source [SID1234641737]). CytomX and Astellas are collaborating on multiple conditionally activated TCB programs with CytomX eligible to receive additional future preclinical, clinical and commercial milestones. CytomX retains a cost share and co-commercialization option on a select number of targets.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The achievement of clinical candidate nomination for the second Probody TCB program in our broad collaboration with Astellas underscores our capabilities in the exciting field of conditionally activated, masked T-cell engaging bispecifics. T-cell engagers offer new possibilities for the treatment of solid tumors and the PROBODY platform may be ideally suited to realizing the potential of this modality," said Sean McCarthy, D. Phil, chief executive officer and chairman of CytomX.

"At Astellas, immuno-oncology is a Primary Focus of our research and development strategy, and the rapidly advancing field of masked bispecific immune cell engagers holds tremendous promise for patients," stated Peter Sandor, M.D., Senior Vice President and Primary Focus Lead, Immuno-Oncology. "We are delighted with the progress in our broad alliance in this area with CytomX and look forward to the continued collaboration successes as we expand our next-generation immuno-oncology therapeutic pipeline to address areas of high unmet medical need."

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

On April 3, 2024 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that members of its senior management team will present at the Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:45 a.m. ET (Press release, CRISPR Therapeutics, APR 3, 2024, View Source [SID1234641736]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.

Clarity enters into Cu-67 SAR-bisPSMA Clinical Supply Agreement with NorthStar supporting late-stage therapy trials

On April 3, 2024 Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, reported the signing of a Clinical Supply Agreement with NorthStar Medical Radioisotopes, LLC (NorthStar) for the production of 67Cu-SAR-bisPSMA drug product for Phase I/II and Phase III trials (Press release, Clarity Pharmaceuticals, APR 3, 2024, View Source [SID1234641735]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, "This important step is yet another differentiating factor that helps Clarity clearly stand out from the rest of the radiopharmaceutical market, making it possible to have therapeutic isotope supply and product manufacture at the same site. We have seen in the past the logistical challenges associated with the separation of radioisotope and final drug product manufacturing with lutetium-177 (Lu-177 or 177Lu) based therapies as it causes delays and inefficiencies, ultimately affecting care for oncology patients waiting for their treatments. Alpha-emitter therapies, such as those involving actinium-225 (Ac-225 or 225Ac) and lead-212 (Pb-212 or 212Pb), are generating interest, but their commercial supply chains are still in the early development phase, and they are currently very difficult to source. These isotopes are also yet to show safety and efficacy in late-stage trials, as opposed to beta emitters, like Cu-67, that have a long history of effectiveness in treating solid tumors.

"The shift away from limited nuclear reactor-based supply, where even today there is an important facility down in Europe due to maintenance issues, is vital in order for radiopharmaceuticals to grow sustainably into the large oncology sector. Copper-67 (Cu-67 or 67Cu) and Targeted Copper Theranostics (TCTs) can now be manufactured and shipped from a single location, a unique feature of Cu-67, due to its ability to be manufactured using electron accelerators.

"By employing TCTs based on Cu-67, Clarity can avoid many of the drawbacks of other therapeutic isotopes, including alpha- and other beta-based therapies. Our TCT therapy programs require only electricity and zinc to make Cu-67, which is now routinely produced in large volumes in the US. The isotope manufacturing is completely modular and scalable, providing significant advantages to increase production in a timely manner. Other advantages of TCTs, such as room temperature manufacturing, reduce the likelihood of batch failures that lead to common supply issues. The fully integrated supply chain of TCTs from production of the isotope to ready-to-use radiopharmaceuticals is unique to Clarity and our platform of therapeutic products under development."

"Given our outstanding clinical trial data to date, we are very excited to secure the supply of Cu-67 and final drug products for the trials with 67Cu-SAR-bisPSMA in prostate cancer as we continue building a sustainable future for radiopharmaceuticals towards our ultimate goal of better treating children and adults with cancer."

The overarching Master Service Agreement and associated Clinical Supply Agreement are effective immediately. The initial supply from NorthStar is expected to occur before the end of calendar year 2024. The Master Services Agreement is for an initial period of 4 years and the Clinical Supply Agreement is for an initial period of 4 years. Cancellation provisions are at industry standard rates.

About SAR Technology
Despite the unique benefits of Cu-67 as a therapeutic isotope for radiopharmaceuticals, historically, the lack of an effective copper chelating technology has limited the clinical development of Cu-67 products and subsequent commercial production of Cu-67. Clarity’s proprietary copper-chelating technology, called "sarcophagine" or SAR Technology, has enabled it to advance the TCT product pipeline into a range of theranostic clinical trials that use copper-64 (Cu-64 or 64Cu) for diagnostic imaging and Cu-67 for therapy. Clarity is currently progressing three key product areas, SAR-bisPSMA, SAR-Bombesin and SARTATE, with three theranostic and four diagnostic clinical trials with a focus on prostate cancer indications.

About SAR-bisPSMA
SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) Technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR Technology prevents copper leakage into the body. SAR-bisPSMA is a TCT that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy.

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA are unregistered products. The data outlined in this announcement has not been assessed by health authorities such as the US Food and Drug Administration (FDA). A clinical development program is currently underway to assess the efficacy and safety of these products. There is no guarantee that these products will become commercially available.